Rinvoq/Rinvoq LQ Prior Authorization Policy
Cigna drug coverage policy IP0682 governing prior authorization criteria, approved indications, durations, prescribing specialist requirements, renewal criteria, and exclusions for Rinvoq (upadacitinib ER tablets) and Rinvoq LQ (oral solution). Applies to multiple inflammatory indications and defines not medically necessary concurrent uses.
Annual Revision conducted on 03/15/2026 with no criteria changes.
Coverage Summary
Coverage stance: Rinvoq (upadacitinib) is covered with criteria under Cigna policy IP0682 effective 03/15/2026. Rinvoq extended-release tablets are the required product for most adult indications (e.g., AD, AS, CD, GCA, nr-axSpA, RA, UC) and are covered when indication-specific criteria are met. Rinvoq LQ oral solution is covered with criteria only for polyarticular juvenile idiopathic arthritis (PJIA) and pediatric psoriatic arthritis in patients 2 to <18 years and is explicitly not substitutable with the tablets. The policy requires prior authorization and follows the documented indication-specific criteria and durations in the scope (initial approvals typically 3–6 months; renewals generally 1 year).
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.